Kelly M.ChinMDaOlivierSitbonMDbMartinDoelbergPhDcJeremyFeldmanMDdJ. Simon R.GibbsMDeEkkehardGrünigMDfMarius M.HoeperMDgNicolasMartinMSccStephen C.MathaiMD, MHShVallerie V.McLaughlinMDiLoïcPerchenetPhDcDavidPochMDjRajanSaggarMDkGéraldSimonneauMDbNazzarenoGalièMDl
doi : 10.1016/j.jacc.2021.07.057
Volume 78, Issue 14, 5 October 2021, Pages 1393-1403
In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with initial double oral therapy.
Jane A.LeopoldMD
doi : 10.1016/j.jacc.2021.08.007
Volume 78, Issue 14, 5 October 2021, Pages 1404-1406
Kuan KenLeeMDaAndaBulargaMDaRachelO’BrienBNbAmy V.FerryPhDaDimitriosDoudesisMScacTakeshiFujisawaPhDaShaunaKellyBScaStaceyStewartBScaRyanWereskiMDaDeniseCranleyBScdEdwin J.R.van BeekMDaeDavid J.LoweMDfDavid E.NewbyMDaMichelle C.WilliamsMBChBaeAlasdair J.GrayMDbcNicholas L.MillsMDac
doi : 10.1016/j.jacc.2021.07.055
Volume 78, Issue 14, 5 October 2021, Pages 1407-1417
Patients with suspected acute coronary syndrome in whom myocardial infarction has been excluded are at risk of future adverse cardiac events.
KavithaChinnaiyanMDaJames L.JanuzziJr.MDb
doi : 10.1016/j.jacc.2021.08.004
Volume 78, Issue 14, 5 October 2021, Pages 1418-1420
Marie-Sophie L.Y.de KoningMDaB. DaanWestenbrinkMD, PhDaSolmazAssaMD, PhDaErwinGarciaPhDbMargery A.ConnellyPhDbDirk J.van VeldhuisenMD, PhDaRobin P.F.DullaartMD, PhDcErikLipsicMD, PhDaPimvan der HarstMD, PhDad
doi : 10.1016/j.jacc.2021.07.054
Volume 78, Issue 14, 5 October 2021, Pages 1421-1432
Circulating ketone bodies (KBs) are increased in patients with heart failure (HF), corresponding with increased cardiac KB metabolism and HF severity. However, the role of circulating KBs in ischemia/reperfusion remains unknown.
Salva R.YuristaMD, PhDAnthonyRosenzweigMDChristopher T.NguyenPhD
doi : 10.1016/j.jacc.2021.08.002
Volume 78, Issue 14, 5 October 2021, Pages 1433-1436
CarlotaOleagaPhDaMichael D.ShapiroMDaJoshuaHayMSaPaul A.MuellerPhDaJoshuaMilesMSaCeciliaHuangMDaEmilyFrizBSaHagaiTavoriPhDaPeter P.TothMD, PhDbcCezaryWójcikMD, PhD, DSaBruce A.WardenPharmDaJonathan Q.PurnellMDaP. BartonDuellMDaNathaliePamirPhDaSergioFazioMD, PhDa
doi : 10.1016/j.jacc.2021.07.056
Volume 78, Issue 14, 5 October 2021, Pages 1437-1449
Monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9i) lower LDL-C by up to 60% and increase plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels by 10-fold.
Sascha N.GoonewardenaMDaRobert S.RosensonMDb
doi : 10.1016/j.jacc.2021.08.006
Volume 78, Issue 14, 5 October 2021, Pages 1450-1452
Matthew W.MartinezMDaJonathan H.KimMD, MScbAnkit B.ShahMD, MPHcDermotPhelanMD, PhDdMichael S.EmeryMD, MSeMeagan M.WasfyMD, MPHfAntonio B.FernandezMDgT. JaredBunchMDhPeterDeanMDiAlfredDanielianMDjSheelaKrishnanMDkAaron L.BaggishMDfThijs M.H.EijsvogelsPhDlEugene H.ChungMD, MScm?Benjamin D.LevineMDn?
doi : 10.1016/j.jacc.2021.08.003
Volume 78, Issue 14, 5 October 2021, Pages 1453-1470
The role of the sports cardiologist has evolved into an essential component of the medical care of athletes. In addition to the improvement in health outcomes caused by reductions in cardiovascular risk, exercise results in adaptations in cardiovascular structure and function, termed exercise-induced cardiac remodeling. As diagnostic modalities have evolved over the last century, we have learned much about the healthy athletic adaptation that occurs with exercise. Sports cardiologists care for those with known or previously unknown cardiovascular conditions, distinguish findings on testing as physiological adaptation or pathological changes, and provide evidence-based and “best judgment” assessment of the risks of sports participation. We review the effects of exercise on the heart, the approach to common clinical scenarios in sports cardiology, and the importance of a patient/athlete-centered, shared decision-making approach in the care provided to athletes.
Tijn P.J.JansenMDa?Regina E.KonstMDa?Suzette E.Elias-SmaleMD, PhDaStijn C.van den OordMD, PhDaPeterOngMD, PhDbAnnemiek M.J.de VosMDcTim P.van de HoefMD, PhDdValeriaParadiesMD, PhDePieter C.SmitsMD, PhDeNielsvan RoyenMD, PhDaPeterDammanMD, PhDa
doi : 10.1016/j.jacc.2021.08.028
Volume 78, Issue 14, 5 October 2021, Pages 1471-1479
Coronary microvascular dysfunction is a highly prevalent condition of both structural and functional coronary disorders in patients with angina and nonobstructive coronary artery disease (ANOCA). Current diagnostic modalities to assess microvascular function are related to prognosis, but these modalities have several technical shortcomings and lack the opportunity to determine true coronary blood flow and microvascular resistance. Intracoronary continuous thermodilution assessment of absolute coronary flow (Q) and microvascular resistance (R) was recently shown to be safe and feasible in ANOCA. Further exploration and implementation could lead to a better understanding and treatment of patients with ANOCA. This review discuss the coronary pathophysiology of microvascular dysfunction, provides an overview of noninvasive and invasive diagnostics, and focuses on the novel continuous thermodilution method. Finally, how these measurements of absolute Q and R could be integrated and how this would affect future clinical care are discussed.
BonnieKyMD, MSCE(Editor-in-Chief, JACC: CardioOncology)ValentinFusterMD, PhD(Editor-in-Chief, JACC)
doi : 10.1016/j.jacc.2021.08.030
Volume 78, Issue 14, 5 October 2021, Pages 1480-1481
Solomon W.BienstockMDPranaiTandonMDUshaGovindarajuluPhDEvanLeibnerMD, PhDBenjamin S.GlicksbergPhDRajeevSamtaniMDGennaroGiustinoMDUmeshGidwaniMDRoopaKohli-SethMDMartin E.GoldmanMD
doi : 10.1016/j.jacc.2021.08.005
Volume 78, Issue 14, 5 October 2021, Pages 1482-1483
GangLuMDZhuoLiPhD
doi : 10.1016/j.jacc.2021.07.051
Volume 78, Issue 14, 5 October 2021, Page e101
ZhenZhouPhDJoanneRyanPhDMichael E.ErnstPharmDAnneMurrayMD, MScMark R.NelsonMBBS, PhD
doi : 10.1016/j.jacc.2021.07.047
Volume 78, Issue 14, 5 October 2021, Page e103
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟